Showing results (441-450 of 576) with videos related to

Sort By:
Pageof 58
Journal of Hematology & Oncology|November 16, 2024
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosisSamuel Urrutia, Hagop M Kantarjian, Farhad Ravandi-Kashani, et al.
Cancer|March 9, 2023
Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulationDaniel Nguyen, Hagop M Kantarjian, Nicholas J Short, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|March 9, 2026
Comprehensive Cytogenomic Profiling of T-Lymphoblastic Leukemia by Optical Genome Mapping, Karyotyping and Next Generation SequencingGuilin Tang, Alexandra Reynolds, Farhad Ravandi-Kashani, et al.
American Journal of Hematology|December 24, 2024
Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic DesignationJayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, et al.
American Journal of Hematology|April 12, 2022
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsKunhwa Kim, Marina Konopleva, Courtney D DiNardo, et al.
Cancer|July 13, 2021
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Abhishek Maiti, Sanam Loghavi, et al.
JAMA Pediatrics|September 5, 2018
Association of Prenatal Maternal Depression and Anxiety Symptoms With Infant White Matter MicrostructureDouglas C Dean, Elizabeth M Planalp, William Wooten, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Cancer|April 16, 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisElias J Jabbour, Koji Sasaki, Farhad Ravandi, et al.
Pageof 58